Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06561321 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma
A Phase 2 study of Palmoplantar Keratoderma, sponsored by Indiana University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT06561321: Recruiting Phase 2 study of Palmoplantar Keratoderma, sponsored by Indiana University.
NCT06561321 is a Phase 2 study of Palmoplantar Keratoderma that is actively recruiting participants, run by Indiana University. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06561321, a Phase 2 study of Palmoplantar Keratoderma, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess adults with palmoplantar keratoderma (thickening skin layer on palms and soles) who are treated with the study drug, tapinarof. This is a naturally occuring compound used for the treatment of psoriasis. This study is being done to find out how well and safe this drug is for stopping or treating keratoderma. This study aims to investigate the positive impacts of daily topical Tapinarof use in the improvement of Keratoderma. Clinical efficacy and safety profile of prescribing Tapinarof for this condition will be evaluated.
Primary Outcome
To evaluate the treatment benefit of Tapinarof applied topically to patients affected with palmoplantar keratoderma. Either an overall change in the PGA score to 0 (clear) or 1 (almost clear) or a decrease from baseline of at least 2 points. Higher scores indicate a worse outcome. Title: PHYSICIAN GLOBAL ASSESSMENT Minimum value: 0 Maximum value: 5
Conditions Studied
Interventions
- DRUG Tapinarof
Study Locations (1)
Indiana
- Indiana University Department of Dermatology - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2024-10-30 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What NCT06561321 shows while recruiting
NCT06561321 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Palmoplantar Keratoderma appearing as the primary indexed condition, and to 1 intervention - of which Tapinarof is the first listed.
NCT06561321 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT06561321 about?
NCT06561321 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma". The purpose of this study is to assess adults with palmoplantar keratoderma (thickening skin layer on palms and soles) who are treated with the study drug, tapinarof. This is a naturally occuring compound used for the treatment of psoriasis. This study is being done to find out how well and safe thi...
What is the current status of trial NCT06561321?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2024-10-30. Estimated completion is 2027-12-31.
What conditions does trial NCT06561321 study?
This clinical trial studies the following conditions: Palmoplantar Keratoderma.
What interventions are being tested in trial NCT06561321?
The interventions under investigation include: Tapinarof (DRUG).
Who is sponsoring clinical trial NCT06561321?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06561321 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06561321's enrollment target sits among peer trials
6 1997th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI